The ability of the immune system to develop Th1 responses against SARS-CoV-2 seems to be clinically important, since COVID-19 patients with severe disease had a significantly diminished Th1 response [42] in response to low levels of induction of IFN-γ by SARS-CoV-2 antigens [43]. The gene discussed is IFNG; the disease is COVID-19.